Cefdinir vs. cephalexin for mild to moderate uncomplicated skin and skin structure infections in adolescents and adults

Current Medical Research and Opinion

Volumn 22, Issue 12, 2006, Pages 2419-2428

  Giordano, Philip A ^a   Elston, Dirk ^b   Akinlade, Bolanle K ^c   Weber, Kurt ^a   Notario, Gerard F ^c   Busman, Todd A ^c   Cifaldi, Mary ^c   Nilius, Angela M ^c  

^a ORLANDO REGIONAL MEDICAL CENTER   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Cefdinir; Cephalexin; Uncomplicated skin and skin structure infections; USSSI

Indexed keywords

CEFALEXIN; CEFDINIR;

ABSCESS; ABSCESS DRAINAGE; ADOLESCENT; ADULT; AGED; CELLULITIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYSIPELAS; FEMALE; FOLLICULITIS; FURUNCULOSIS; GASTROENTERITIS; HUMAN; IMPETIGO; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY; NAUSEA; NEEDLE BIOPSY; OUTCOME ASSESSMENT; PARONYCHIA; PHASE 4 CLINICAL TRIAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SKIN INFECTION; SKIN STRUCTURE; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VAGINA MYCOSIS; WOUND INFECTION;

ABSCESS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELLULITIS; CEPHALEXIN; CEPHALOSPORINS; FEMALE; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; WOUND INFECTION;

EID: 33845995794     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X148355     Document Type: Conference Paper

References (30)

1. Doern GV, Jones RN, Pfaller MA, et al. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program [United States and Canada, 1997). Diagn Microbiol Infect Dis 1999;34:65-72
2. Swartz MN. Cellulitis and subcutaneous tissue infections, In: Mandell GL, Bennett JE, Dolan R, editors. Principles and practice of infectious diseases. New York: Churchill Livingstone Inc.; 2000. p. 1037-57
3. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Uncomplicated and complicated skin and skin structure infections - developing antimicrobial drugs for treatment. Draft Guidance July 1998. At: http://www.fda.gov/cder/guidance/index.htm [accessed: July 7, 2006]
4. Elston DM. Optimal antibacterial treatment of uncomplicated skin and skin structure infections: applying a novel treatment algorithm. J Drugs Dermatol 2005;4[Suppl 6):S15-S19
5. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-406
6. NPA™ Plus (National Prescription Audit Plus). IMS Health. April, 2006
7. Physician Drug & Diagnosis Audit (PDDA) from Verispan, January 2006 - March 2006
8. Nolen T. Comparative studies of cefprozil in the management of skin and soft-tissue infections. Eur J Clin. Microbiol Infect Dis 1994;13:866-71
9. Schatz BS, Karavokiros KT, Taeubel MA, et al. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten. Ann Pharmacother 1996;30:258-68
10. Wilson SE. The management of skin and skin structure infections in children, adolescents and adults: a review of empiric antimicrobial therapy. Int J Clin Pract 1998;52:414-7
11. Wiseman LR, Benfield P. Cefprozil: a review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential. Drugs 1993;45:295-317
12. Tack KJ, Keyserling CH, McCarty J, et al. Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. Antimicrob Agents Chemother 1997;41:739-42
13. Bucko AD, Hunt BJ, Kidd SL, et al. Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections. Clin Ther 2002;24:1134-47
14. Parish LC, Routh HB, Miskin B, et al. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int J Clin Pract 2000;54:497-503
15. Zetola N, Francis JS, Nuermberger EL, et al. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 2005;5:275-86
16. King MD, Humphrey BJ, Wang YF, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006;144:309-17
17. Moran GJ, Amii RN, Abrahamian FM, et al. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis 2005;11:928-30
18. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999. MMWR Morb Mortal Wkly Rep 1999;48:707-10
19. Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999;29:1128-32
20. Omnicef® Prescribing Information. Abbott Laboratories ©2005. At: www.abbott.com [accessed July 7, 2006]
21. Reflex® Prescribing Information. Advancis Pharmaceutical Corporation ©2005. At: http://www.advancispharm.com/products/keflex/ [accessed July 7, 2006]
22. National Committee for Clinical Laboratory Standards, 2000. Performance standards for antimicrobial disk susceptibility tests; approved standard NCCLS document M2-A7 and 10th informational supplement (M100-S10[M2])
23. National Committee for Clinical Laboratory Standards, 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-fifth edition, M7-A5 and 10th informational supplement (M100 S10[M7])
24. Matilde-Sanchez MM, Chen X. Choosing the analysis population in non-inferiority studies: per-protocol or intent-to-treat. Statist Med 2006;25:1169-81
25. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. CLSI document M100-S16 (ISBN 1-56238-588-7). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2006
26. Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin- resistant Staphylococcus aureus. Pediatr Infect Dis J 2004;23:123-7
27. Young DM, Harris HW, Charlebois ED, et al. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Arch Surg 2004;139:947-53
28. Fridkin SK, Hageman JC, Morrison M, et al.; for the Active Bacterial Core Surveillance Program of the Emerging Infections Program. Methicillin-resistant Staphylococcus aureus disease in three communities. New Engl J Med 2005;352:1436-44
29. Chambers HF. Community-associated MRSA - resistance and virulence converge. New Engl J Med 2005;352:1485-7
30. Madaras-Kelly KJ, Arbogast R, Jue S. Increased therapeutic failure for cephalexin versus comparator antibiotics in the treatment of uncomplicated outpatient cellulitis. Pharmacotherapy 2000;20:199-205